-
Innovation Ranking
Innovation Ranking – Shanghai Junshi Bioscience Co Ltd
Shanghai Junshi Biomedical Technology Co Ltd, formerly Shanghai Junshi Bioscience Co Ltd is a biopharmaceutical company that discovers, develops and commercializes drugs for infectious diseases, oncology, metabolic, auto-immunity and neurologic indications. It is investigating JS001 antibody against various malignant tumors; JS003, JS006, and JS201 to treat solid tumors; JS004 for melanoma, hodgkin lymphoma and lung carcinoma; JS101 for the treatment of breast cancer; JS108 for pancreatic, triple negative breast cancer, small cell lung cancer. The company is also evaluates JS002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Gastric Cancer Drug Details: Toripalimab (Tuoyi, Loqtorzi) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Hepatocellular Carcinoma Drug Details: Toripalimab (Tuoyi, Loqtorzi) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Anal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Anal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Anal Cancer Drug Details: Toripalimab (Tuoyi, Loqtorzi) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Toripalimab (Tuoyi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Ewing Sarcoma Drug Details: Toripalimab (Tuoyi, Loqtorzi) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Squamous Cell Carcinoma Drug Details: Toripalimab (Tuoyi, Loqtorzi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Neuroendocrine Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Neuroendocrine Carcinoma Drug Details: Toripalimab (Tuoyi, Loqtorzi) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Throat Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Throat Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Throat Cancer Drug Details: Toripalimab (Tuoyi, Loqtorzi) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Toripalimab in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Toripalimab in Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Toripalimab in Rhabdomyosarcoma Drug Details: Toripalimab (Tuoyi, Loqtorzi) is a monoclonal antibody,...